Novel biological therapies for the treatment of diabetic foot ulcers

• Published in: Expert opinion on biological therapy Vol. 17; no. 8; p. 979
• Main Authors: Adeghate, Jennifer, Nurulain, Syed, Tekes, Kornélia, Fehér, Erzsébet, Kalász, Huba, Adeghate, Ernest
• Format: Journal Article
• Language: English
• Published: England 03.08.2017
• Subjects: Biological Products - therapeutic use; Diabetic Foot - drug therapy; Diabetic Foot - etiology; Diabetic Foot - therapy; Diabetic Neuropathies - complications; Humans; Hypoglycemic Agents - therapeutic use; Immunomodulation; Intercellular Signaling Peptides and Proteins - therapeutic use; Stem Cell Transplantation; Urokinase-Type Plasminogen Activator - therapeutic use; Wound Healing; diabetic angiopathy; hyperglycemia; diabetic neuropathy; Diabetes mellitus; diabetic foot; therapy; ulcer; long-term complications
• DOI: 10.1080/14712598.2017.1333596

The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.